ACE has carefully monitored the research on biologic use during pregnancy in response to the many ACE members who are thinking of starting a family and have concerns about continuing their medications.
We have previously reported on the study by Dr. Mary De Vera, Assistant Professor at the University of British Columbia’s Faculty of Pharmaceutical Sciences, and her team on “Patterns of medication use before, during, and after pregnancy among women with systemic lupus erythematosus: A population-based study”.
Dr. De Vera’s team assessed the use of medications in pregnant women with lupus in British Columbia. Most pregnancy trimesters in the study were exposed to hydroxychloroquine and/or chloroquine (41 to 45% of exposed pregnancy trimesters). The research observed an increase in glucocorticosteroid (like prednisone) exposures during pregnancy, as well as post-delivery. Findings emphasized the importance of counseling women regarding childbearing decisions as well as the need for evaluation of the risk-benefit profiles of medications in pregnancy.